Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
- Written by PR Newswire
![]() | ![]() |
Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study
PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM,...









